Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer

Optimum的主要研究人员开发了肿瘤穿透微粒（TPMs），这是一种针对腹膜腔独特解剖特性量身定制的一流输送系统。TPMs是一种多组分、多功能、生物相容性、可生物降解、控释的微米级聚合物颗粒。TPMs旨在靶向、穿透并将药效学优化的药物水平输送到腹膜肿瘤的浅层和深层。TPMs代表了一个可用于递送小分子治疗药物、生物制剂、基因载体和显像剂的递送平台。第一代TPM （TPM001）装载紫杉醇，以胰腺癌为第一适应症。目标是开发一种有效的局部控制转移性胰腺癌和腹膜肿瘤的治疗方法。

The lead investigators at Optimum developed tumor-penetrating microparticles (TPMs), a first-in-class delivery system tailored to the unique anatomical properties of the peritoneal cavity. TPMs are multicomponent, multifunctional, biocompatible, biodegradable, controlled-release polymeric micron-size particles. TPMs are designed to target, penetrate and deliver pharmacodynamically optimized drug levels to the superficial and deep layers of peritoneal tumors. TPMs represent a delivery platform that can be used to deliver small molecule therapeutics, biologics, gene vectors and imaging agents. The first generation TPM (TPM001) is loaded with paclitaxel, with pancreatic cancer as the first indication. The goal is to develop an effective treatment for locoregional control of metastatic pancreatic cancer and, more generally, peritoneal tumors. The BrIDGs team has made progress towards the completion of the following studies on TPM001: - Manufacture of Good Manufacturing Practice (GMP) drug product - Formulation development - Pharmacokinetic/absorption, distribution, metabolism, and excretion (PK/ADME) studies - Investigational New Drug (IND)-directed toxicology